PL378130A1 - Pochodne kwasu 3-(2-fenylooksazol-4-ilometoksy)-cykloheksylometoksyoctowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń - Google Patents

Pochodne kwasu 3-(2-fenylooksazol-4-ilometoksy)-cykloheksylometoksyoctowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń

Info

Publication number: PL378130A1
Authority: PL; Poland
Prior art keywords: cyclohexylmethoxy; oxazol; arteriosclerosis; diabetes; methoxy
Prior art date: 2003-02-27

Application number

PL378130A

Other languages

English (en)

Inventor

Christian Stapper

Heiner Glombik

Eugen Falk

Jochen Goerlitzer

Dirk Gretzke

Stefanie Keil

Hans-Ludwig Schaefer

Wolfgang Wendler

Original Assignee

Sanofi-Aventis Deutschland Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-02-27

Filing date

2004-02-19

Publication date

2006-03-06

2004-02-19 Application filed by Sanofi-Aventis Deutschland Gmbh filed Critical Sanofi-Aventis Deutschland Gmbh

2006-03-06 Publication of PL378130A1 publication Critical patent/PL378130A1/pl

Links

CQWYYUYAROQPOK-UHFFFAOYSA-N 2-[[3-[(2-phenyl-1,3-oxazol-4-yl)methoxy]cyclohexyl]methoxy]acetic acid Chemical class C1(=CC=CC=C1)C=1OC=C(N1)COC1CC(CCC1)COCC(=O)O CQWYYUYAROQPOK-UHFFFAOYSA-N 0.000 title 1
206010003210 Arteriosclerosis Diseases 0.000 title 1
101150014691 PPARA gene Proteins 0.000 title 1
208000011775 arteriosclerosis disease Diseases 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
208000001072 type 2 diabetes mellitus Diseases 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Diabetes (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Hematology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Pyrrole Compounds (AREA)

PL378130A 2003-02-27 2004-02-19 Pochodne kwasu 3-(2-fenylooksazol-4-ilometoksy)-cykloheksylometoksyoctowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń PL378130A1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE10308355A DE10308355A1 (de)	2003-02-27	2003-02-27	Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel

Publications (1)

Publication Number	Publication Date
PL378130A1 true PL378130A1 (pl)	2006-03-06

Family

ID=32920629

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PL378437A PL378437A1 (pl)	2003-02-27	2004-02-19	Pochodne kwasu 3-metylo-2-(3-(2-fenylooksazol-4-ilometoksy)-cykloheksanokarbonyloamino)-masłowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń
PL378130A PL378130A1 (pl)	2003-02-27	2004-02-19	Pochodne kwasu 3-(2-fenylooksazol-4-ilometoksy)-cykloheksylometoksyoctowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń
PL377735A PL377735A1 (pl)	2003-02-27	2004-02-19	Pochodne kwasu 4-(3-(2-fenylooksazol-4-ilometoksy)- cykloheksyloksy)- propano-1-karboksylowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL378437A PL378437A1 (pl)	2003-02-27	2004-02-19	Pochodne kwasu 3-metylo-2-(3-(2-fenylooksazol-4-ilometoksy)-cykloheksanokarbonyloamino)-masłowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL377735A PL377735A1 (pl)	2003-02-27	2004-02-19	Pochodne kwasu 4-(3-(2-fenylooksazol-4-ilometoksy)- cykloheksyloksy)- propano-1-karboksylowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń

Country Status (34)

Country	Link
US (5)	US7365084B2 (pl)
EP (3)	EP1599452B1 (pl)
JP (3)	JP2006519194A (pl)
KR (3)	KR20050106462A (pl)
CN (3)	CN100398526C (pl)
AR (3)	AR043427A1 (pl)
AT (3)	ATE365159T1 (pl)
AU (3)	AU2004215672B2 (pl)
BR (3)	BRPI0407814A (pl)
CA (3)	CA2517386A1 (pl)
CL (2)	CL2004000392A1 (pl)
CO (2)	CO5690580A2 (pl)
DE (4)	DE10308355A1 (pl)
DK (3)	DK1599453T3 (pl)
EC (2)	ECSP055985A (pl)
ES (3)	ES2287700T3 (pl)
HR (3)	HRP20050742A2 (pl)
IL (2)	IL170316A (pl)
MA (3)	MA27736A1 (pl)
MX (3)	MXPA05008951A (pl)
NO (3)	NO20054396L (pl)
OA (2)	OA13034A (pl)
PA (1)	PA8596801A1 (pl)
PE (3)	PE20050292A1 (pl)
PL (3)	PL378437A1 (pl)
PT (3)	PT1599453E (pl)
RS (1)	RS20050594A (pl)
RU (3)	RU2005129995A (pl)
SA (1)	SA04250153A (pl)
TN (2)	TNSN05206A1 (pl)
TW (3)	TW200500349A (pl)
UY (2)	UY28209A1 (pl)
WO (3)	WO2004076428A1 (pl)
ZA (2)	ZA200505768B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7576131B2 (en)	1999-06-04	2009-08-18	Metabolex, Inc.	Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6262118B1 (en) *	1999-06-04	2001-07-17	Metabolex, Inc.	Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7399777B2 (en) *	2001-08-31	2008-07-15	Sanofi-Aventis Deutschland Gmbh	Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10308353A1 (de) *	2003-02-27	2004-12-02	Aventis Pharma Deutschland Gmbh	Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038403B4 (de) *	2004-08-07	2006-08-31	Sanofi-Aventis Deutschland Gmbh	Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
DE102004039532B4 (de)	2004-08-14	2006-09-21	Sanofi-Aventis Deutschland Gmbh	Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039509B4 (de) *	2004-08-14	2006-09-21	Sanofi-Aventis Deutschland Gmbh	Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004039533B4 (de)	2004-08-14	2006-09-28	Sanofi-Aventis Deutschland Gmbh	Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004060227B3 (de)	2004-12-15	2006-07-20	Sanofi-Aventis Deutschland Gmbh	Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
GT200600218A (es) *	2005-06-10	2007-03-28		Formulación y proceso de compresión directa
WO2007039177A2 (en)	2005-09-29	2007-04-12	Sanofi-Aventis	Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
US8128969B2 (en)	2006-08-10	2012-03-06	Mimozax Co., Ltd.	Hypoglycemic composition containing acacia bark derivative
US8481778B2 (en)	2007-08-16	2013-07-09	Solvay (Societe Anonyme)	Process for the preparation of esters of 4-fluorosubstituted 3-oxo-alcanoic acids
NZ587261A (en) *	2008-02-29	2012-05-25	Nissan Chemical Ind Ltd	Process for producing thiophene compound and intermediate thereof
US7615661B2 (en) *	2008-03-12	2009-11-10	International Flavors & Fragrances Inc.	Thioester compounds and their use in fragrance or flavor applications
KR102592503B1 (ko)	2017-12-13	2023-10-23	캐논 가부시끼가이샤	카트리지
CN109810071B (zh) *	2019-03-28	2023-04-21	中国科学院成都生物研究所	一种miRNA生物合成抑制剂

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2663336B1 (fr)	1990-06-18	1992-09-04	Adir	Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2663464B1 (fr) *	1990-06-19	1992-09-11	Commissariat Energie Atomique	Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication.
IL108633A (en)	1993-02-15	1998-07-15	Wellcome Found	History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
IL108634A0 (en)	1993-02-15	1994-05-30	Wellcome Found	Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
JP3144624B2 (ja)	1995-06-02	2001-03-12	杏林製薬株式会社	Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
IL125071A0 (en)	1996-01-17	1999-01-26	Novo Nordisk As	Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives their preparation and use
HU227021B1 (en)	1996-08-30	2010-05-28	Novo Nordisk As	Glp-1 derivatives
TW492957B (en)	1996-11-07	2002-07-01	Novartis Ag	N-substituted 2-cyanopyrrolidnes
DK0958296T3 (da)	1996-12-31	2003-08-18	Reddys Lab Ltd Dr	Heterocykliske forbindelser, fremgangsmåde til deres fremstilling og farmaceutiske præparater, der indeholder dem, og deres anvendelse i behandlingen af diabetes og beslægtede sygdomme
DE19726167B4 (de) *	1997-06-20	2008-01-24	Sanofi-Aventis Deutschland Gmbh	Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
AU757693B2 (en)	1997-07-16	2003-03-06	Novo Nordisk A/S	Fused 1,2,4-thiadiazine derivatives, their preparation and use
CO4970713A1 (es)	1997-09-19	2000-11-07	Sanofi Synthelabo	Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
WO1999046232A1 (en) *	1998-03-10	1999-09-16	Ono Pharmaceutical Co., Ltd.	Carboxylic acid derivatives and drugs containing the same as the active ingredient
DE19823831A1 (de)	1998-05-28	1999-12-02	Probiodrug Ges Fuer Arzneim	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
SE9801992D0 (sv)	1998-06-04	1998-06-04	Astra Ab	New 3-aryl-2-hydroxypropionic acid derivative I
MA26634A1 (fr)	1998-06-04	2004-12-20	Astra Ab	Nouveaux derives de l'acide 3-aryl propionique et analogues
US6221897B1 (en) *	1998-06-10	2001-04-24	Aventis Pharma Deutschland Gmbh	Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828114A1 (de)	1998-06-24	2000-01-27	Probiodrug Ges Fuer Arzneim	Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de)	1998-06-24	2000-01-05	Probiodrug Ges Fuer Arzneim	Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
US6664281B1 (en) *	1998-08-27	2003-12-16	Ono Pharmaceutical Co., Ltd.	Carboxylic acid derivatives and drugs containing the same as the active ingredient
DE19845405C2 (de) *	1998-10-02	2000-07-13	Aventis Pharma Gmbh	Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en)	1999-01-08	1999-02-24	Alizyme Therapeutics Ltd	Inhibitors
DE19916108C1 (de) *	1999-04-09	2001-01-11	Aventis Pharma Gmbh	Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
AU3956900A (en)	1999-04-16	2000-11-02	Boehringer Ingelheim International Gmbh	Substituted imidazoles, their preparation and use
US6908926B1 (en) *	1999-04-16	2005-06-21	Novo Nordisk A/S	Substituted imidazoles, their preparation and use
PT1177176E (pt) *	1999-04-28	2006-08-31	Aventis Pharma Gmbh	Derivados de acidos triarilicos como ligandos de receptores ppar.
RU2267484C2 (ru)	1999-04-28	2006-01-10	Авентис Фарма Дойчланд Гмбх	Производные диариловой кислоты и фармацевтическая композиция на их основе
WO2000066585A1 (en)	1999-04-30	2000-11-09	Neurogen Corporation	9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS
GB9911863D0 (en)	1999-05-21	1999-07-21	Knoll Ag	Therapeutic agents
AU773505B2 (en)	1999-06-18	2004-05-27	Merck & Co., Inc.	Arylthiazolidinedione and aryloxazolidinedione derivatives
JP2003504082A (ja)	1999-07-09	2003-02-04	コヘージョンテクノロジーズ，インコーポレイテッド	エカリンポリペプチド、エカリンをコードするポリヌクレオチド、及びその利用のための方法
AU768310B2 (en)	1999-07-29	2003-12-04	Eli Lilly And Company	Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists
CN1372541A (zh) *	1999-09-01	2002-10-02	阿文蒂斯药物德国有限公司	磺酰基甲酰胺衍生物、其制备方法及其作为药物的应用
TWI302149B (en)	1999-09-22	2008-10-21	Bristol Myers Squibb Co	Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
DE60008921T2 (de)	1999-12-03	2005-01-20	Astrazeneca Ab	Kristalline form von (s)-2-ethoxy-3-4-(2-4-methansulfonyloxyphenyl-ethoxy)phenyl]propansäure
SE9904413D0 (sv)	1999-12-03	1999-12-03	Astra Ab	Comminuted form
DK1283735T4 (da)	2000-03-31	2013-02-04	Royalty Pharma Collection Trust	Fremgangsmåde til forbedring signalering af øceller ved diabetes mellitus og til forebyggelse deraf
AU4882801A (en)	2000-04-25	2001-11-07	Kyorin Pharmaceutical Co. Ltd.	Novel stable crystal of thiazolidinedione derivative and process for producing the same
DE60129806T2 (de)	2000-04-28	2007-12-06	Asahi Kasei Pharma Corp.	Neue bizyklische verbindungen
EP1280777B1 (en)	2000-05-11	2005-11-23	Bristol-Myers Squibb Company	Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
AU2001264977B2 (en)	2000-05-30	2005-04-14	Merck & Co., Inc.	Melanocortin receptor agonists
YU91002A (sh)	2000-06-09	2006-05-25	Aventis Pharma Deutschland	Derivati acilfenil-karbamida, postupak za njihovu proizvodnju i njihova primena kao leka
DE10038709A1 (de)	2000-08-09	2002-02-28	Aventis Pharma Gmbh	Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
EP1182251A1 (en) *	2000-08-11	2002-02-27	Yissum Research Development Company of the Hebrew University of Jerusalem	Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkB
KR20030027054A (ko) *	2000-08-23	2003-04-03	일라이 릴리 앤드 캄파니	옥사졸릴-아릴프로피온산 유도체 및 ｐｐａｒ효능제로서의 그의 용도
WO2002018355A1 (en)	2000-08-23	2002-03-07	Eli Lilly And Company	Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
TWI243162B (en)	2000-11-10	2005-11-11	Taisho Pharmaceutical Co Ltd	Cyanopyrrolidine derivatives
AU2002222573A1 (en)	2000-12-05	2002-06-18	Kyorin Pharmaceutical Co. Ltd.	Substituted carboxylic acid derivatives
GB0031103D0 (en) *	2000-12-20	2001-01-31	Glaxo Group Ltd	Chemical compounds
PT1345895E (pt)	2000-12-21	2007-02-28	Sanofi Aventis Deutschland	Novas difenilazetidinonas, processo para a sua preparação, fármacos contendo estes compostos e sua utilização para o tratamento de distúrbios do metabolismo lipídico
EP1726586A1 (en) *	2000-12-25	2006-11-29	Ono Pharmaceutical Co., Ltd.	Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient
JP2004529097A (ja) *	2001-02-15	2004-09-24	ファイザー・プロダクツ・インク	Ｐｐａｒアゴニスト
PE20021091A1 (es)	2001-05-25	2003-02-04	Aventis Pharma Gmbh	Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
IL159002A0 (en) *	2001-06-07	2004-05-12	Lilly Co Eli	Modulators of peroxisome proliferator activated receptors (ppar)
DE10154689A1 (de)	2001-11-09	2003-05-22	Probiodrug Ag	Substituierte Aminoketonverbindungen
WO2003004458A1 (en)	2001-07-03	2003-01-16	Biovitrum Ab	New compounds
FR2827859B1 (fr)	2001-07-30	2005-09-23	Lipha	Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
RU2330846C2 (ru)	2001-08-31	2008-08-10	Санофи-Авентис Дойчланд Гмбх	Диарилциклоалкильные производные, способ их получения и их применение в качестве ppar-активаторов
JP2005517008A (ja)	2002-02-05	2005-06-09	イーライ・リリー・アンド・カンパニー	Ｐｐａｒモジュレーターとして用いるためのウレアリンカー誘導体
DE10215908B4 (de)	2002-04-11	2005-08-18	Aventis Pharma Deutschland Gmbh	Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10215907A1 (de)	2002-04-11	2003-11-06	Aventis Pharma Gmbh	Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
DE10225635C1 (de)	2002-06-07	2003-12-24	Aventis Pharma Gmbh	N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
PL374860A1 (pl)	2002-07-09	2005-11-14	Bristol-Myers Squibb Company	Podstawione pochodne heterocykliczne korzystne jako środki przeciwko cukrzycy i otyłości i sposób ich stosowania
US7148246B2 (en) *	2003-02-27	2006-12-12	Sanofi-Aventis Deutschland Gmbh	Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals

2003
- 2003-02-27 DE DE10308355A patent/DE10308355A1/de not_active Withdrawn
2004
- 2004-02-19 PL PL378437A patent/PL378437A1/pl not_active Application Discontinuation
- 2004-02-19 DK DK04712494T patent/DK1599453T3/da active
- 2004-02-19 OA OA1200500247A patent/OA13034A/en unknown
- 2004-02-19 WO PCT/EP2004/001586 patent/WO2004076428A1/de not_active Ceased
- 2004-02-19 JP JP2006501886A patent/JP2006519194A/ja active Pending
- 2004-02-19 CN CNB2004800054985A patent/CN100398526C/zh not_active Expired - Fee Related
- 2004-02-19 DE DE502004009453T patent/DE502004009453D1/de not_active Expired - Lifetime
- 2004-02-19 HR HR20050742A patent/HRP20050742A2/xx not_active Application Discontinuation
- 2004-02-19 RU RU2005129995/04A patent/RU2005129995A/ru not_active Application Discontinuation
- 2004-02-19 AT AT04712490T patent/ATE365159T1/de not_active IP Right Cessation
- 2004-02-19 DK DK04712503T patent/DK1599455T3/da active
- 2004-02-19 OA OA1200500248A patent/OA13035A/en unknown
- 2004-02-19 CN CNB2004800054379A patent/CN100439345C/zh not_active Expired - Fee Related
- 2004-02-19 AT AT04712494T patent/ATE430738T1/de not_active IP Right Cessation
- 2004-02-19 WO PCT/EP2004/001579 patent/WO2004076427A1/de not_active Ceased
- 2004-02-19 ES ES04712490T patent/ES2287700T3/es not_active Expired - Lifetime
- 2004-02-19 PL PL378130A patent/PL378130A1/pl not_active Application Discontinuation
- 2004-02-19 KR KR1020057016023A patent/KR20050106462A/ko not_active Ceased
- 2004-02-19 DE DE502004004139T patent/DE502004004139D1/de not_active Expired - Lifetime
- 2004-02-19 CA CA002517386A patent/CA2517386A1/en not_active Abandoned
- 2004-02-19 MX MXPA05008951A patent/MXPA05008951A/es active IP Right Grant
- 2004-02-19 HR HR20050743A patent/HRP20050743A2/xx not_active Application Discontinuation
- 2004-02-19 AT AT04712503T patent/ATE435217T1/de not_active IP Right Cessation
- 2004-02-19 RS YUP-2005/0594A patent/RS20050594A/sr unknown
- 2004-02-19 CN CNB2004800054769A patent/CN100439347C/zh not_active Expired - Fee Related
- 2004-02-19 KR KR1020057015851A patent/KR20050105492A/ko not_active Ceased
- 2004-02-19 RU RU2005129992/04A patent/RU2005129992A/ru not_active Application Discontinuation
- 2004-02-19 PT PT04712494T patent/PT1599453E/pt unknown
- 2004-02-19 ES ES04712494T patent/ES2326418T3/es not_active Expired - Lifetime
- 2004-02-19 BR BRPI0407814-4A patent/BRPI0407814A/pt not_active IP Right Cessation
- 2004-02-19 DK DK04712490T patent/DK1599452T3/da active
- 2004-02-19 EP EP04712490A patent/EP1599452B1/de not_active Expired - Lifetime
- 2004-02-19 BR BRPI0407907-8A patent/BRPI0407907A/pt not_active IP Right Cessation
- 2004-02-19 JP JP2006501892A patent/JP2006519199A/ja active Pending
- 2004-02-19 WO PCT/EP2004/001578 patent/WO2004076426A1/de not_active Ceased
- 2004-02-19 HR HR20050744A patent/HRP20050744A2/xx not_active Application Discontinuation
- 2004-02-19 AU AU2004215672A patent/AU2004215672B2/en not_active Ceased
- 2004-02-19 RU RU2005130002/04A patent/RU2005130002A/ru not_active Application Discontinuation
- 2004-02-19 BR BRPI0407758-0A patent/BRPI0407758A/pt not_active IP Right Cessation
- 2004-02-19 EP EP04712503A patent/EP1599455B1/de not_active Expired - Lifetime
- 2004-02-19 AU AU2004215673A patent/AU2004215673B2/en not_active Ceased
- 2004-02-19 CA CA002517381A patent/CA2517381A1/en not_active Abandoned
- 2004-02-19 PT PT04712503T patent/PT1599455E/pt unknown
- 2004-02-19 PL PL377735A patent/PL377735A1/pl not_active Application Discontinuation
- 2004-02-19 EP EP04712494A patent/EP1599453B1/de not_active Expired - Lifetime
- 2004-02-19 MX MXPA05008988A patent/MXPA05008988A/es active IP Right Grant
- 2004-02-19 CA CA002516620A patent/CA2516620A1/en not_active Abandoned
- 2004-02-19 AU AU2004215677A patent/AU2004215677B2/en not_active Ceased
- 2004-02-19 MX MXPA05008995A patent/MXPA05008995A/es active IP Right Grant
- 2004-02-19 ES ES04712503T patent/ES2329366T3/es not_active Expired - Lifetime
- 2004-02-19 DE DE502004009690T patent/DE502004009690D1/de not_active Expired - Lifetime
- 2004-02-19 PT PT04712490T patent/PT1599452E/pt unknown
- 2004-02-19 JP JP2006501885A patent/JP2006519193A/ja active Pending
- 2004-02-19 KR KR1020057015995A patent/KR20050106461A/ko not_active Ceased
- 2004-02-25 TW TW093104704A patent/TW200500349A/zh unknown
- 2004-02-25 TW TW093104697A patent/TW200508210A/zh unknown
- 2004-02-25 TW TW093104705A patent/TW200510352A/zh unknown
- 2004-02-27 AR ARP040100629A patent/AR043427A1/es not_active Application Discontinuation
- 2004-02-27 AR ARP040100635A patent/AR043432A1/es not_active Application Discontinuation
- 2004-02-27 PA PA20048596801A patent/PA8596801A1/es unknown
- 2004-02-27 PE PE2004000203A patent/PE20050292A1/es not_active Application Discontinuation
- 2004-02-27 CL CL200400392A patent/CL2004000392A1/es unknown
- 2004-02-27 US US10/788,997 patent/US7365084B2/en not_active Expired - Fee Related
- 2004-02-27 UY UY28209A patent/UY28209A1/es unknown
- 2004-02-27 US US10/789,017 patent/US7335671B2/en not_active Expired - Lifetime
- 2004-02-27 CL CL200400391A patent/CL2004000391A1/es unknown
- 2004-02-27 AR ARP040100636A patent/AR043433A1/es not_active Application Discontinuation
- 2004-02-27 PE PE2004000206A patent/PE20040959A1/es not_active Application Discontinuation
- 2004-02-27 US US10/788,996 patent/US7259177B2/en not_active Expired - Lifetime
- 2004-02-27 UY UY28210A patent/UY28210A1/es unknown
- 2004-02-27 PE PE2004000205A patent/PE20050293A1/es not_active Application Discontinuation
- 2004-06-09 SA SA04250153A patent/SA04250153A/ar unknown
2005
- 2005-07-19 ZA ZA200505768A patent/ZA200505768B/en unknown
- 2005-07-19 ZA ZA200505765A patent/ZA200505765B/en unknown
- 2005-08-16 IL IL170316A patent/IL170316A/en not_active IP Right Cessation
- 2005-08-16 IL IL170314A patent/IL170314A/en not_active IP Right Cessation
- 2005-08-26 CO CO05085508A patent/CO5690580A2/es not_active Application Discontinuation
- 2005-08-26 TN TNP2005000206A patent/TNSN05206A1/en unknown
- 2005-08-26 MA MA28459A patent/MA27736A1/fr unknown
- 2005-08-26 CO CO05085499A patent/CO5690578A2/es not_active Application Discontinuation
- 2005-08-26 TN TNP2005000204A patent/TNSN05204A1/en unknown
- 2005-08-26 MA MA28460A patent/MA27737A1/fr unknown
- 2005-08-26 EC EC2005005985A patent/ECSP055985A/es unknown
- 2005-08-26 EC EC2005005986A patent/ECSP055986A/es unknown
- 2005-08-26 MA MA28465A patent/MA27742A1/fr unknown
- 2005-09-22 NO NO20054396A patent/NO20054396L/no unknown
- 2005-09-22 NO NO20054408A patent/NO20054408L/no unknown
- 2005-09-22 NO NO20054398A patent/NO20054398L/no unknown
2007
- 2007-08-16 US US11/839,950 patent/US20080015238A1/en not_active Abandoned
2008
- 2008-01-14 US US12/013,806 patent/US7872034B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
RU2005130002A (ru)	2006-01-27
AU2004215672A1 (en)	2004-09-10
SA04250153A (ar)	2005-12-03
TNSN05204A1 (en)	2007-06-11
EP1599455A1 (de)	2005-11-30
IL170314A (en)	2010-11-30
JP2006519193A (ja)	2006-08-24
DK1599452T3 (da)	2007-10-01
US7259177B2 (en)	2007-08-21
TW200500349A (en)	2005-01-01
HRP20050744A2 (en)	2006-09-30
US20080167354A1 (en)	2008-07-10
TW200508210A (en)	2005-03-01
WO2004076427A1 (de)	2004-09-10
PL378437A1 (pl)	2006-04-03
CA2517381A1 (en)	2004-09-10
US20080015238A1 (en)	2008-01-17
EP1599452A1 (de)	2005-11-30
JP2006519194A (ja)	2006-08-24
KR20050105492A (ko)	2005-11-04
NO20054396L (no)	2005-11-11
TW200510352A (en)	2005-03-16
AU2004215672B2 (en)	2010-01-07
MA27737A1 (fr)	2006-02-01
JP2006519199A (ja)	2006-08-24
NO20054396D0 (no)	2005-09-22
PT1599453E (pt)	2009-07-14
MA27742A1 (fr)	2006-02-01
NO20054398L (no)	2005-11-02
OA13034A (en)	2006-11-10
NO20054408L (no)	2005-11-23
PA8596801A1 (es)	2004-09-16
US20040209920A1 (en)	2004-10-21
BRPI0407758A (pt)	2006-02-14
BRPI0407907A (pt)	2006-02-14
ES2287700T3 (es)	2007-12-16
DK1599453T3 (da)	2009-08-24
AU2004215677A1 (en)	2004-09-10
US7872034B2 (en)	2011-01-18
MXPA05008951A (es)	2005-11-04
DE10308355A1 (de)	2004-12-23
ZA200505768B (en)	2005-11-23
WO2004076426A1 (de)	2004-09-10
CA2517386A1 (en)	2004-09-10
CN1753881A (zh)	2006-03-29
DK1599455T3 (da)	2009-11-09
AU2004215677B2 (en)	2010-01-07
PT1599455E (pt)	2009-09-29
ES2329366T3 (es)	2009-11-25
AR043427A1 (es)	2005-07-27
NO20054398D0 (no)	2005-09-22
AR043433A1 (es)	2005-07-27
US7365084B2 (en)	2008-04-29
RU2005129995A (ru)	2006-01-27
US20050215596A1 (en)	2005-09-29
HRP20050742A2 (en)	2006-09-30
ZA200505765B (en)	2006-05-31
PE20050293A1 (es)	2005-05-24
CO5690580A2 (es)	2006-10-31
EP1599453A1 (de)	2005-11-30
CN100398526C (zh)	2008-07-02
PL377735A1 (pl)	2006-02-20
ATE435217T1 (de)	2009-07-15
CL2004000391A1 (es)	2005-01-07
UY28209A1 (es)	2004-09-30
OA13035A (en)	2006-11-10
ECSP055986A (es)	2006-01-16
PE20040959A1 (es)	2005-01-17
CN1753879A (zh)	2006-03-29
DE502004009690D1 (de)	2009-08-13
AU2004215673B2 (en)	2009-10-01
MXPA05008995A (es)	2005-10-18
NO20054408D0 (no)	2005-09-22
CN1756748A (zh)	2006-04-05
CA2516620A1 (en)	2004-09-10
PT1599452E (pt)	2007-09-12
CO5690578A2 (es)	2006-10-31
MXPA05008988A (es)	2005-10-18
ATE365159T1 (de)	2007-07-15
DE502004009453D1 (de)	2009-06-18
US7335671B2 (en)	2008-02-26
WO2004076428A1 (de)	2004-09-10
US20050101637A1 (en)	2005-05-12
MA27736A1 (fr)	2006-02-01
RS20050594A (sr)	2007-12-31
PE20050292A1 (es)	2005-05-24
AU2004215673A1 (en)	2004-09-10
TNSN05206A1 (en)	2007-06-11
BRPI0407814A (pt)	2006-02-14
CL2004000392A1 (es)	2005-04-22
KR20050106462A (ko)	2005-11-09
AR043432A1 (es)	2005-07-27
EP1599452B1 (de)	2007-06-20
EP1599455B1 (de)	2009-07-01
DE502004004139D1 (de)	2007-08-02
ECSP055985A (es)	2006-01-16
HRP20050743A2 (en)	2006-08-31
IL170316A (en)	2010-11-30
CN100439347C (zh)	2008-12-03
EP1599453B1 (de)	2009-05-06
RU2005129992A (ru)	2006-02-10
UY28210A1 (es)	2004-09-30
ATE430738T1 (de)	2009-05-15
ES2326418T3 (es)	2009-10-09
CN100439345C (zh)	2008-12-03
KR20050106461A (ko)	2005-11-09

Legal Events

Date	Code	Title	Description
2011-12-30	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
PL378130A1 (pl)	2006-03-06	Pochodne kwasu 3-(2-fenylooksazol-4-ilometoksy)-cykloheksylometoksyoctowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń
NO20020764D0 (no)	2002-02-15	Benzoesyrederivater for behandling av diabetes mellitus
NO20015909D0 (no)	2001-12-03	Anvendelse av (-) (3-trihalometylfenoksy) (4-halofenyl) eddiksyrederivater for behandling av insulinresistens, type 2diabetes, hyperlipidemi og hyperurisemi
UA104987C2 (uk)	2014-04-10	Похідні 3-(2,6-диметилбензилокси)фенілоцтової кислоти
EG24124A (en)	2008-07-07	Pharmaceutical compositions for the treatment of type-II diabetes mellitus
AU2003279442A1 (en)	2004-04-23	2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
PL375878A1 (pl)	2005-12-12	Pochodne N-podstawionego kwasu 1H-indolo-5-propionowego jako agoniści PPAR do leczenia cukrzycy
NO20025883D0 (no)	2002-12-06	Tiazolidinonsalt for behandling av diabetes mellitus
IL181010A0 (en)	2007-07-04	2-{3,'2- (phenyl)-oxazol-4-ylmethoxyl-cyclohexylmethoxy}-propionic acid derivatives used as ppar ligands (peroxisome proliferator-activated receptors) for the treatment of hyperlipidaemie and diabetes
AU2003292449A1 (en)	2004-07-09	Process for the preparation of 3-(2-(3,4-dimethoxybenzoyl)-4,5- dimethoxyphenyl) -pentan-2-one
AU2002235042A1 (en)	2002-10-03	Composition for treating arteriosclerosis comprising 3-(4'-hydroxyl-3',5'-dimethoxyphenyl)propionic acid or its derivatives
DK1789402T3 (da)	2010-03-22	2-{-3-2-(phenyl)-oxazol-4-ylmethoxymethyl-cyclohexylmethoxy)-propionsyrederivater som PPAR-ligander (peroxisomen-proliferator-aktiverede receptorer) til behandling af hyperlipidæmi og diabetes
AU2003255850A1 (en)	2004-02-09	Process for the preparation of modification i of n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridinesulfonamide
AU2002230023A1 (en)	2002-08-19	Salts of 3-4(4-(2-phenoxazin- or phenothiazin-10-yl)alkoxy)phenyl)-2-alkoxypropanoic acid derivatives with ppar activity for the treatment of hyperlipimedia and type ii diabetes
UA34041A (uk)	2001-02-15	Спосіб лікування цукрового діабету
HK1056551A (en)	2004-02-20	Thiazolidinedione salt for treatment of diabetes mellitus
AU2002350563A1 (en)	2003-05-26	Pharmaceutical composition comprising a glitazone and a thiazolidinedione derivative, and use thereof for treating diabetes
HK1069107A (en)	2005-05-13	The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus
AU2001262786A1 (en)	2002-08-28	Use of l-2-oxothiazolidine-4-carboxylic acid for the treatment of type 2 diabetes
GB9926061D0 (en)	2000-01-12	Compositions for the treatment of diabetes mellitus
AU2002338753A1 (en)	2003-06-17	Pharmaceutical composition comprising an alpha-glucosidase inhibitor and a thiazolidinedione derivative, and a use thereof for treating diabetes
HK1091470A (en)	2007-01-19	Process for the synthesis of 3-(3-fluoro-4-hydroxyphenyl)-7-hydroxynaphthonitrile
HK1094700A (en)	2007-04-04	3-(4-benzyloxyphenyl)propanoic acid derivatives